A CRO FOCUSED ON A NICHE WITHIN NUCLEAR MEDICINE: CLINICAL TRIALS WITH RADIOPHARMACEUTICALS.

Lippia Alba SL proposes itself as a CRO specializing in clinical trials with radiopharmaceuticals in Spain, coordinating a network of PET/SPECT sites and authorized radiopharmacies.

Mitigated risks

• Delays in the site selection process.
• Delays in regulatory approvals and radiological licenses.
• Failures or variability in site quality (image, IMP handling).
• Tracer losses due to transport or inadequate coordination.
• Unexpected logistical/customs/radionuclide permit costs.
• Failed patient visits due to IMP difficulties.

What sets us apart

• Proprietary database with technical information on radiopharmacy units and nuclear medicine services throughout Spain.
• Collaboration with the Spanish Society of Radiopharmacy (SERFA).
• Framework Collaboration Agreements with Radiopharmacy Sites and Units.
• Streamlined Site Selection using proprietary AI tools.
• Coordinated work with the Spanish Agency for Medicines and Health Products (AEMPS) and the Nuclear Safety Council (CSN) to reduce trial approval times.
• Collaboration Agreements with companies specializing in the transport of hazardous substances.
• Use of validated and flexible SaaS platforms for CTMS, e-TMF, and e-CRF.
• Multidisciplinary team with in-depth knowledge of the national market and expertise in Clinical Trials, Nuclear Safety, Pharmacy, Radiopharmacy, and Nuclear Medicine.